AUPH
Price
$7.75
Change
+$0.08 (+1.04%)
Updated
Apr 17 closing price
Capitalization
1.06B
13 days until earnings call
NAMS
Price
$16.34
Change
+$0.31 (+1.93%)
Updated
Apr 17 closing price
Capitalization
1.79B
19 days until earnings call
Ad is loading...

AUPH vs NAMS

Header iconAUPH vs NAMS Comparison
Open Charts AUPH vs NAMSBanner chart's image
Aurinia Pharmaceuticals
Price$7.75
Change+$0.08 (+1.04%)
Volume$929.34K
Capitalization1.06B
NewAmsterdam Pharma
Price$16.34
Change+$0.31 (+1.93%)
Volume$277.25K
Capitalization1.79B
AUPH vs NAMS Comparison Chart
Loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. NAMS commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Hold and NAMS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (AUPH: $7.75 vs. NAMS: $16.34)
Brand notoriety: AUPH and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 62% vs. NAMS: 25%
Market capitalization -- AUPH: $1.06B vs. NAMS: $1.79B
AUPH [@Biotechnology] is valued at $1.06B. NAMS’s [@Biotechnology] market capitalization is $1.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, AUPH is a better buy in the long-term than NAMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 3 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).

  • AUPH’s TA Score: 3 bullish, 7 bearish.
  • NAMS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than AUPH.

Price Growth

AUPH (@Biotechnology) experienced а +5.59% price change this week, while NAMS (@Biotechnology) price change was +9.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

AUPH is expected to report earnings on Jul 31, 2025.

NAMS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($1.79B) has a higher market cap than AUPH($1.06B). AUPH YTD gains are higher at: -13.697 vs. NAMS (-36.420). AUPH has higher annual earnings (EBITDA): 31.7M vs. NAMS (-241.49M). NAMS has more cash in the bank: 834M vs. AUPH (358M). NAMS has less debt than AUPH: NAMS (448K) vs AUPH (79.4M). AUPH has higher revenues than NAMS: AUPH (235M) vs NAMS (45.6M).
AUPHNAMSAUPH / NAMS
Capitalization1.06B1.79B59%
EBITDA31.7M-241.49M-13%
Gain YTD-13.697-36.42038%
P/E Ratio193.75N/A-
Revenue235M45.6M515%
Total Cash358M834M43%
Total Debt79.4M448K17,723%
FUNDAMENTALS RATINGS
AUPH: Fundamental Ratings
AUPH
OUTLOOK RATING
1..100
18
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
89
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
43
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AUPHNAMS
RSI
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
59%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
42%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
46%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
52%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
53%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
58%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Ad is loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRAX13.840.16
+1.17%
NYLI CBRE Global Infrastructure Class A
CSMUX21.390.18
+0.85%
Carillon Scout Mid Cap R-6
BMPEX23.570.03
+0.13%
Beck Mack + Oliver Partners
FIRCX9.08N/A
N/A
Fidelity Advisor Intl Real Estate C
PMBCX33.33N/A
N/A
Principal MidCap C

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+1.93%
QURE - NAMS
52%
Loosely correlated
+38.45%
CMRX - NAMS
49%
Loosely correlated
-0.12%
CRDF - NAMS
39%
Loosely correlated
+1.42%
AUPH - NAMS
34%
Loosely correlated
N/A
CGON - NAMS
32%
Poorly correlated
+2.08%
More